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Abstract
Background: The circumsporozoite protein (CS protein) on the malaria parasites in mosquitoes plays an important
role in sporogony in mosquitoes. The RTS,S/AS01 malaria vaccine candidate, which has shown significant efficacy
against clinical malaria in a large Phase 3 trial, targets the Plasmodium falciparum CS protein, but the ability of
serum from vaccinated individuals to inhibit sporogony in mosquitoes has not been evaluated.
Methods: Previously a double-blind, randomized trial of RTS,S/AS01 vaccine, as compared with rabies vaccine, in
five- to 17-month old children in Tanzania was conducted. In this study, polyclonal human antibodies were purified
from the pools of sera taken one month after the third vaccination. IgGs were purified from four pools of sera from
25 RTS,S/AS01 vaccinated children each, and two pools of sera from 25 children vaccinated with rabies vaccine
each. The ability of antibodies to inhibit P. falciparum oocyst formation and/or sporogony in the mosquito host was
evaluated by a standard membrane-feeding assay. The test antibodies were fed on day 0 (at the same time as the
gametocyte feed), or on days 3 or 6 (serial-feed experiments). The oocyst and sporozoite counts were performed
on days 8 and 16, respectively. In addition, two human anti-CS monoclonal antibodies (mAb) and a control mAb
were also evaluated.
Results: Polyclonal anti-CS IgG preparations from RTS,S-vaccinated children tested at concentrations of 149-210
ELISA units (EU)/ml did not show significant inhibition in oocyst and sporozoite formation when the antibodies
were fed with gametocytes at the same time, or later (serial-feed experiments). Similarly, anti-CS mAbs tested at
6,421 or 7,122 EU/ml did not show reduction in oocyst and sporozoite formation.
Conclusions: This study does not support the concept that anti-CS antibodies induced by the RTS,S/AS01 vaccines
in humans noticeably reduce malaria transmission by blocking P. falciparum sporozoite development or salivary
gland invasion in mosquitoes when taken up during feeding.
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Background
There are two ways malaria vaccines could prevent trans-
mission of malaria from one immunized individual to an-
other susceptible individual. One is through the induction
of pre-erythrocytic or blood-stage immunity that prevent
(or dramatically reduces) gametocyte formation in humans,
and the other one is through the induction of immunity
that acts in the mosquito to prevent parasites from reach-
ing the salivary glands. The latter strategy relies on the ac-
tivity of immune effectors ingested with the blood meal
against parasite and mosquito antigens that are exposed to
the blood meal [1-4].
The RTS,S/AS01 malaria candidate vaccine is being de-
veloped with the aim of reducing the clinical disease asso-
ciated with Plasmodium falciparum malaria in children in
Africa when administered to infants and/or young chil-
dren. While the vaccine has shown a significant efficacy
with respect to clinical malaria in a Phase 3 trial [5], the
ability of RTS,S/AS01 to reduce malaria transmission
has not been evaluated. The RTS,S/AS01 vaccine target
antigen is the circumsporozoite protein (CS protein), a
412 amino acids protein abundantly associated with the
sporozoite surface. CS protein, the expression of which
starts in the oocyst [6-8], plays an important role in
sporogony [9,10].
Modelling studies have been conducted, and clinical
studies are being considered, to evaluate the potential for
RTS,S/AS01, if used in mass vaccination programmes
achieving high population coverage, to reduce transmis-
sion of malaria through the ability of pre-erythrocytic im-
munity to reduce incidence of new infection [11]. In
contrast, this study evaluates the potential for serum from
RTS,S/AS01 immunized children, when ingested by the
mosquito with a blood meal, to inhibit sporogony in mos-
quitoes. The rationale for testing this hypothesis comes
from two observations. First, it is known that antibodies
ingested by the mosquito during a blood meal can traverse
the midgut epithelium and reach the haemolymph [12].
Secondly, it has been demonstrated that mosquitoes in-
fected with transgenic fungi which expressed single light
chain anti-CS antibody showed fewer sporozoites in the
salivary glands compared to the mosquitoes infected
with the wild type fungi [13]. In addition, a recent study
indirectly supports the idea of transmission blocking by
an anti-CS antibody: antibodies against circumsporozoite
protein-binding protein (CSPBP) significantly reduced the
sporozoite load in salivary glands of Plasmodium berghei
infected mosquitoes [14]. It is, therefore, possible that
anti-CS antibodies induced by RTS,S/AS01 vaccination
and ingested by the mosquito during a blood meal may
affect oocyst formation and/or sporogony in the mosquito
host. Past attempts at evaluating the effect of anti-
sporozoite sera on sporogony have led to conflicting re-
sults [12,15-18]. This is the first study to evaluate the
effect of serum samples from children who were immu-
nized with a vaccine against CS protein.
In this study, the ability of antibodies from children
vaccinated with RTS,S/AS01 to inhibit oocyst formation
and/or sporogony in the mosquito host was tested using
a standard membrane-feeding assay (SMFA). The post-
vaccination sera collected in a double-blind, randomized
trial of RTS,S/AS01 vaccine as compared with rabies
vaccine in five- to 17-month old children in Korogwe,
Tanzania were used. The clinical study showed that RTS,S/
AS01 provided a 53% (95% confidence interval (CI), 28 to
69; P < 0.001) protection against malaria over an average
eight-month period [19]. In the current study, in vitro cul-
tured P. falciparum gametocytes were mixed with test anti-
bodies and fed to laboratory-reared Anopheles mosquitoes.
After a few days, mosquitoes were dissected and successful
progression of the parasite cycle was evaluated by counting
oocysts on the midgut basal lamina, or sporozoites in the
salivary glands, depending on the numbers of days passed
after the infectious feeding. In addition, serial feedings were
used, where mosquitoes were first fed on gametocytes
without antibodies and then later fed on test antibodies.
These serial feedings mimic the fact that in nature mosqui-
toes feed repeatedly. In addition, human monoclonal anti-
bodies (mAb) against CS [20] were also evaluated.
Methods
Clinical trial and antibody sample preparation
A Phase 2b clinical trial of RTS,S/AS01 vaccine (GlaxoS-
mithKline (GSK) Biologicals, Belgium) was conducted in
children in Korogwe, Tanzania, as part of a multicentre,
observer-blinded, randomized, controlled trial reported
previously [19]. The study was prospectively registered at
ClinicalTrials.gov (NCT00380393) and approved by the
Tanzanian Medical Research Coordinating Committee,
and the Western Institutional Review Board in Seattle.
The study was overseen by an Independent Data Monitor-
ing Committee and local safety monitors, and conducted
in accordance with the Helsinki Declaration of 1964 (re-
vised 1996) and Good Clinical Practice guidelines. Written
informed consent was obtained from the parent or guard-
ian of each child. In brief, children between five and
17 months of age at the time of first vaccination received
either RTS,S/AS01 vaccine or a control rabies vaccine,
intramuscularly at zero, one and two months.
Because of the small volume of sera available from each
child, the current study was based on six serum pools.
Each pool was made using sera from 25 vaccinated sub-
jects bled at one month post-third vaccine dose. Four
pools were made from children who received RTS,S/AS01
vaccines, and the other two pools were from rabies-
immunized children.
The human anti-RTS, S monoclonal antibodies target-
ing the repeat region of the CS protein (mAb, MAL1C
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and MAL2A) were generated as described previously
[20]. As a control, a malaria-unrelated human mAb was
used for each assay.
Anti-CS ELISA
Anti-CS IgG concentration in each sample was mea-
sured using a validated anti-CS ELISA as described pre-
viously [20]. The anti-CS IgG concentration is expressed
as ELISA units per milliliter (EU/ml).
IgG purification and standard membrane-feeding assay
(SMFA)
IgG from pooled serum samples were purified via Pro-
tein G affinity chromatography (Pierce, Rockford, IL,
USA) according to the manufacturer’s instructions and
adjusted to a final concentration of 20 mg/ml in phos-
phate buffered saline (PBS). Four total IgGs from the
RTS,S/AS01 group are designated as CS-1, -2, -3 and -4,
and two IgGs from the control (rabies) group are desig-
nated as Contl-1 and -2 in this study.
The standardized methodology for performing the
SMFA has been described previously [21]. Briefly, 16-18
day old gametocyte cultures of the P. falciparum NF54
line (200 μl of 50% haematocrit culture adjusted to 0.15-
0.2% stage V gametocytaemia) were mixed with 60 μl of
a test sample, and the final mixture was immediately fed
to ~50 female Anopheles stephensi (Nijmegen strain, three
to six days old) mosquitoes through a membrane-feeding
apparatus. The human serum and red blood cells used for
the cultures were purchased from Interstate Blood Bank,
Inc, Memphis, TN, USA. The polyclonal IgGs were tested
at 3.75 mg/ml of total IgG concentration. For the mAb,
the concentration of 0.231 mg/ml was used. The level of
anti-CS specific antibody of each sample (either polyclonal
or monoclonal antibodies) in a test feeder was calcu-
lated based on EU/ml value of the stock IgG and the di-
lution factor to make the final mixture for a feeding
experiment. For example, CS-1 sample showed 805 EU/ml
in the stock IgG (at 20 mg/ml of total IgG), and the anti-
CS IgG level was calculated as 151 EU/ml in a test
feeder (at 3.75 mg/ml of total IgG). Mosquitoes were
kept for eight days and dissected (20 mosquitoes per sam-
ple) to enumerate oocysts in their midguts. Only midguts
from mosquitoes with any eggs at the time of dissection
were analysed.
For the sporozoite count, mosquitoes were kept for
16 days and dissected to collect salivary glands (12 mos-
quitoes per sample). The salivary glands from an individ-
ual mosquito were transferred to a tube containing 50 μl
of PBS, then homogenized gently by repeated pipetting.
Twenty μl of suspension were transferred to a haemocyt-
ometer and the number of sporozoites was determined
under a phase-contrast microscope.
For a serial-feed experiment, ~50 female An. stephensi
were fed gametocyte cultures as in a regular SMFA, but
without any test antibody, on day 0 (100 μl infected eryth-
rocytes and 160 μl normal human serum). On days 3 or 6,
the mosquitoes were fed again with a test antibody and
50% haematocrit of uninfected erythrocytes (60 μl test
antibody diluted in PBS was mixed with 100 μl uninfected
erythrocytes and 100 μl normal human serum). The final
protein concentration of a test IgG in a feeder was the
same as a regular SMFA: 3.75 mg/ml for polyclonal IgGs
and 0.231 mg/ml for mAbs. The oocyst and sporozoite
counts were performed on days 8 and 16 post-infectious
feed, respectively. In these experiments, salivary glands
from 12 mosquitoes for each test sample were pooled in
300 μl PBS for counting.
Statistical analysis
Per cent (%) inhibition of mean oocyst intensity (PIm[o])
was calculated as: 100 × {1 - (mean number of oocysts in
the test group)/(mean number of oocysts in the control
groups)}. Similarly,% inhibition of mean sporozoite inten-
sity (PIm[s]) was calculated. For the calculations, an arith-
metic mean was used, instead of geometric mean or
median, because previous work on oocyst intensity has
shown a zero inflated negative binomial distribution fits
very well to the data [21]. Other studies also utilized simi-
lar negative binomial models for the oocyst data [22,23].
For sporozoite intensity, a study has shown that the log
sporozoite intensity is approximately linearly related to
the log oocyst intensity [24] in the case of P. falciparum
infection in Anopheles gambiae mosquitoes. Therefore, it
seems like a reasonable assumption to use arithmetic
means for sporozoite analyses as well. The% inhibition of
oocyst prevalence (PIp[o]) was evaluated as: 100 × {1-
(proportion of mosquitoes with any oocysts in the test
group)/(proportion of mosquitoes with any oocyst in the
control group)}. The lowest number of sporozoite de-
tected by this method (the haemocytometer measurement
described above) was 3 × 103 per mosquito. Therefore, the
mosquito with ‘zero’ sporozoites might have some sporo-
zoites (<3 × 103) if they were examined with a more sensi-
tive method. For this reason,% inhibition of sporozoite
prevalence was not analysed in this study. For estimating
the PIm[s] and its CI, the value of 1.5 × 103 (the half of
the minimum non-zero count in the current study) was
assigned for a mosquito with ‘zero’ sporozoites.
The CI for PIm[o] of each test sample was calculated
using a zero-inflated negative binomial random effects
model which was similar to the method described previ-
ously [21]. For this study the zero-inflation factor and the
random effects standard errors for the container of mos-
quitoes (COM, viz, a group of mosquitoes which were
housed in the same container and were fed the same cul-
ture and test antibodies) and feeds were estimated from
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the previous study [21]. Under the model, new data (in
which means were obtained from the current study)
were simulated and the middle 95% was used as the CI.
For the CI of PIp[o] and PIm[s], it was not possible to use
the same model as the historical data were not sufficient
(in case of PIp[o]) or no such data were available (PIm[s]).
Therefore, the method of Miettinen and Nurminen [25]
was used for PIp[o] and the negative binomial method
for PIm[s]. Both methods did not account for the ran-
dom effect for COM and feeds, as there were no data to
estimate those effects, and hence the results will tend
to be anti-conservative, ie, reject more often than the
nominal 0.05 level.
For the polyclonal IgG data, a meta regression model
was used to compare PIm[o] values between anti-CS
IgGs (four samples) and control IgGs (two samples). The
same model was utilized to compare PIm[s] values of
the two groups for the regular feed. Since the sporozoite
counts were done with pools of salivary glands of 12
mosquitoes per group in the serial-feed experiments, a
t-test was used to compare the PIm[s] data. The PIp[o]
data of two groups were compared by a logistic regres-
sion allowing for over-dispersion.
To combine the data from two independent feeding ex-
periments, a normal fixed effects meta analysis method on
the log relative risks was used. The metaphor R package
was used for the analysis [26].
All statistical tests were performed in R (version 2.15.2)
and two-sided p-values <0.05 were considered significant.
Results
Transmission-blocking activity of IgGs from human sera
of RTS,S-vaccinated children
The purified total IgGs of CS-1, -2, -3 and -4 (at
3.75 mg/ml) corresponded to anti-CS concentrations of
151, 210, 149 and 156 EU/ml, respectively, while control
IgGs, Contl-1 and -2, showed less than 0.1 EU/ml. The
concentrations of anti-CS antibodies (149-210 EU/ml)
were lower than levels observed at peak (one month post
dose 3, geometric mean of 539.6 EU/ml [19]), but higher
than that observed a few months later (71.9 EU/ml 1.5-
to 7.5 (mean of 5) months after the peak) [19], and simi-
lar to peak levels in young infants (199.9 EU/ml) [27]
and in 1-4 years old children (207 EU/ml) [28].
Table 1 shows% inhibition (and the CI) of mean oocyst
intensity (PIm[o]), oocyst prevalence (PIp[o]), and mean
sporozoite intensity (PIm[s]) of each anti-CS IgG com-
pared to the Control IgGs. Since there were huge varia-
tions in oocyst and sporozoite numbers even within the
same COM, the estimates of% inhibition had large CIs
(Table 1). Therefore, four anti-CS IgGs and two control
IgGs were compared as groups. In terms of the oocyst
intensity, the model estimated that the mean in the anti-
CS IgG group was 1.0 (95% CI, -2.7 to 4.7; p = 0.59)
higher than that in the control. The odds ratio of oocyst
prevalence in anti-CS IgG group compared to control
was estimated as 2.7 (95% CI, 0.7 to 10.7; p = 0.15). For
the sporozoite intensity, the model estimated the mean
in anti-CS IgG group was 1.6 × 103 (95% CI, -2.9 to
6.2 × 103; p = 0.48) higher. Taken together, there was no
significant inhibition in anti-CS IgGs compared to the
control IgGs for any readouts.
Since CS protein is only synthesized six days or later
after a gametocyte feed in a mosquito [9], a serial-feed ex-
periment, where the same mosquitoes were fed again with
test antibodies on days 3 or 6 after gametocyte feed, was
performed. The inhibitory activities of each individual test
IgG are shown in Table 2 (day 3 serial feed) and Table 3
(day 6 serial feed). Similar to the regular feed (Table 1),
the variations in the oocyst numbers were large. There-
fore, the effect of anti-CS IgG was also evaluated as a
group. For the oocyst intensity, the mean in the anti-CS
IgG group was 2.7 (95% CI, -6.2 to 11.6; p = 0.55) or 2.2
(95% CI, -3.9 to 8.3; p = 0.48) higher than those in control
in the day 3 or 6 serial feeds, respectively. The odds ratio
of oocyst prevalence in the anti-CS IgG group compared
to control was 0.32 (95% CI, 0.02 to 6.0; p = 0.49) in the
day 3 serial feed. In the day 6 serial feed, since only one
mosquito (who was fed with CS-2) with zero oocysts (all
other mosquitoes in both groups had more than one oo-
cyst), no comparison was performed for the prevalence
data. For the sporozoite numbers, there was no signifi-
cant difference between the two groups (p = 0.34 for day
3 serial feed, and p = 0.43 for day 6 serial feed).
Transmission-blocking activity of human monoclonal
anti-CS antibodies
Two human monoclonal antibodies (MAL1C and MAL2A)
were also evaluated in this study. Using the mAb, it was
possible to test at higher CS-specific antibody concentra-
tion in the membrane-feeding assay. The anti-CS specific
antibody levels of MAL1C and MAL2A were 7,122 and
6,421 EU/ml when they were tested at 0.231 mg/ml protein
concentration.
In the first experiment with mAb, MAL1C, MAL2A
and control (Contl) mAb were fed along with the gameto-
cyte culture. While MAL1C mAb did not show any inhib-
ition, MAL2A showed 61% inhibition (95% CI, -24 to 87;
p = 0.089) in oocyst intensity (PIm[o]) and 32% inhibition
(95% CI, 7 to 55; p = 0.018) in oocyst prevalence (PIp[o])
in the first feeding experiment (Table 4). A second experi-
ment was performed to confirm this inhibitory activity,
but here, MAL2A did not show any inhibition. When the
data from the two feeding experiments were combined,
MAL2A showed 21% inhibition (95% CI, -73 to 64;
p = 0.551) in PIm[o] and 7% inhibition (95% CI, -9 to 21;
p = 0.361) in PIp[o]. The 2 mAbs did not show any inhib-
ition in sporozoite counts (Table 4).
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Serial-feed experiments were also performed with the
mAb, similar to the polyclonal antibodies, on days 3
(Table 5) or 6 (Table 6) after gametocyte feed. Neither of
the mAb showed significant inhibition in oocyst intensity
(PIm[o]) or oocyst prevalence (PIp[o]) in both experiments.
For the inhibition in sporozoite intensity (PIm[s]), the
inhibitory activity of MAL1C was not consistent (53
and -129% inhibitions in the day 3 and 6 serial feeds, re-
spectively), and MAL2A mAb did not show any inhib-
ition in both serial-feeds.
Table 2 Transmission-blocking activities of human polyclonal IgGs fed three days post-infected blood meala
Sample Mean oocb PIm[o]c p-valued Mosquitoe PIp[o]f p-valueg Mean Spzh PIm[s]i
CS-1 30.0 1 0.93 3/20 13 0.07 71.3 -184
(0, 75) (-148, 62) (-1, 35)
CS-2 29.9 1 0.92 0/20 -3 0.48 49.4 -97
(2, 56) (-139, 62) (-15, 14)
CS-3 37.6 -24 0.66 0/20 -3 0.48 56.9 -127
(5, 69) (-190, 51) (-15, 14)
CS-4 34.5 -14 0.88 3/20 13 0.07 35.4 -41
(0, 87) (-175, 57) (-1, 35)
Contl-1 25.5 N/A N/A 0/20 N/A N/A 43.1 N/A
(1, 80)
Contl-2 35.0 N/A N/A 1/20 N/A N/A 7.0 N/A
(0, 83)
aAll purified IgGs were tested at 3.75 mg/ml and fed three days post-infected blood meal.
bArithmetic mean (range) of oocysts per mosquito midgut.
cPer cent inhibition of mean oocyst intensity (PIm[o]) and the 95% confidence interval (95% CI).
dTwo-sided p-values for testing whether PIm[o] is significantly different from 0.
eNumber of mosquitoes without any oocysts/number of mosquitoes examined.
fPer cent inhibition of prevalence of mosquitoes with oocysts (PIp[o]) and the 95% CI.
gp-values of PIp[o].
hNumber of sporozoites (×103) per mosquito calculated from a pool of salivary glands of 12 mosquitoes.
iPer cent inhibition of mean sporozoite intensity (PIm[s]) calculated with the average of sporozoites counts of Contl-1 and Contl-2.
Table 1 Transmission-blocking activities of human polyclonal IgGs fed with infected blood meala
Sample Mean oocb PIm[o]c p-valued Mosquitoe PIp[o]f p-valueg Mean Spzh PIm[s]i p-valuej
CS-1 10.7 4 0.87 1/20 -9 0.36 14.8 -51 0.32
(0, 34) (-142, 64) (-30, 14) (0, 52.3) (-257, 31)
CS-2 10.8 3 0.88 1/20 -9 0.36 15.3 -56 0.29
(0, 20) (-134, 65) (-30, 14) (0, 43.0) (-274, 30)
CS-3 12.2 -9 0.95 1/20 -9 0.36 10.1 -3 0.94
(0, 38) (-174, 59) (-30, 14) (0, 19.3) (-152, 54)
CS-4 14.2 -27 0.67 1/20 -9 0.36 9.1 6 0.89
(0, 26) (-208, 53) (-30, 14) (0, 41.3) (-150, 61)
Contl-1 10.6 N/A N/A 2/20 N/A N/A 8.9 N/A N/A
(0, 49) (0, 22.8)
Contl-2 11.7 N/A N/A 3/20 N/A N/A 10.6 N/A N/A
(0, 34) (0, 25.3)
aAll purified IgGs were tested at 3.75 mg/ml and fed with infected blood meal at the same time.
bArithmetic mean (range) of oocysts per mosquito midgut.
cPer cent inhibition of mean oocyst intensity (PIm[o]) and the 95% confidence interval (95% CI).
dTwo-sided p-values for testing whether PIm[o] is significantly different from 0.
eNumber of mosquitoes without any oocysts/number of mosquitoes examined.
fPer cent inhibition of prevalence of mosquitoes with oocysts (PIp[o]) and the 95% CI.
gp-values of PIp[o].
hArithmetic mean (range) of sporozoites (×103) per mosquito.
iPer cent inhibition of mean sporozoite intensity (PIm[s]) and the 95% CI.
jp-values of PIm[s].
Miura et al. Malaria Journal 2014, 13:263 Page 5 of 9
http://www.malariajournal.com/content/13/1/263
Table 3 Transmission-blocking activities of human polyclonal IgGs fed six days post-infected blood meala
Sample Mean oocb PIm[o]c p-valued Mosquitoe PIp[o]f p-valueg Mean Spzh PIm[s]i
CS-1 37.7 -13 0.82 0/20 0 1.00 91.1 -2
(19, 82) (-176, 54) (-10, 16)
CS-2 33.7 -1 0.97 1/20 5 0.15 72.7 19
(0, 54) (-151, 63) (-4, 24)
CS-3 35.8 -8 0.94 0/20 0 1.00 87.4 3
(5, 72) (-157, 59) (-10, 16)
CS-4 34.6 -4 0.98 0/20 0 1.00 83.8 7
(6, 74) (-144, 61) (-10, 16)
Contl-1 33.2 N/A N/A 0/20 N/A N/A 84.8 N/A
(10, 62)
Contl-2 33.3 N/A N/A 0/20 N/A N/A 94.7 N/A
(10, 77)
aAll purified IgGs were tested at 3.75 mg/ml and fed six days post-infected blood meal.
bArithmetic mean (range) of oocysts per mosquito midgut.
cPer cent inhibition of mean oocyst intensity (PIm[o]) and the 95% confidence interval (95% CI).
dTwo-sided p-values for testing whether PIm[o] is significantly different from 0.
eNumber of mosquitoes without any oocysts/number of mosquitoes examined.
fPer cent inhibition of prevalence of mosquitoes with oocysts (PIp[o]) and the 95% CI.
gp-values of PIp[o].
hNumber of sporozoites (×103) per mosquito calculated from a pool of salivary glands of 12 mosquitoes.
iPer cent inhibition of mean sporozoite intensity (PIm[s]) calculated with the average of sporozoites counts of Contl-1 and Contl-2.
Table 4 Transmission-blocking activities of human mAb fed with infected blood meala
Sample Mean oocb PIm[o]c p-valued Mosquitoe PIp[o]f p-valueg Mean Spzh PIm[s]i p-valuej
First experiment
MAL1C 18.8 3 0.94 3/20 11 0.29 37.9 -21 0.72
(0, 55) (-191, 67) (-14, 33) (0, 94.0) (-254, 58)
MAL2A 7.5 61 0.09 7/20 32 0.02 39.0 -24 0.63
(0, 37) (-24, 87) (7, 55) (0.5, 89.0) (-215, 51)
Contl 19.5 N/A N/A 1/20 N/A N/A 31.2 N/A N/A
(0, 36) (0, 146.5)
Second experiment
MAL1C 33.8 -21 0.71 0/20 0 1.000 N.D. N.D. N.D.
(12, 59) (-248, 56) (-19, 16)
MAL2A 42.2 -51 0.46 0/20 0 1.000 N.D. N.D. N.D.
(13, 71) (-344, 49) (-19, 16)
Contl 27.9 N/A N/A 0/20 N/A N/A N.D. N.D. N.D.
(1, 55)
aAll mAb were tested at 0.231 mg/ml and fed with infected blood meal at the same time.
bArithmetic mean (range) of oocysts per mosquito midgut.
cPer cent inhibition of mean oocyst intensity (PIm[o]) and the 95% confidence interval (95% CI).
dTwo-sided p-values for testing whether PIm[o] is significantly different from 0.
eNumber of mosquitoes without any oocysts/number of mosquitoes examined.
fPer cent inhibition of prevalence of mosquitoes with oocysts (PIp[o]) and the 95% CI.
gp-values of PIp[o].
hArithmetic mean (range) of sporozoites (×103) per mosquito. No sporozoite count in the second experiment.
iPer cent inhibition of mean sporozoite intensity (PIm[s]) and the 95% CI.
jp-values of PIm[s].
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Discussion
Studies have shown that anti-CS antibodies [13,29] or
anti-CSPBP antibody [14] can reduce sporozoite numbers
in mosquitoes. Another study has shown that the injection
of CS protein or peptide into mosquitoes on day 7 or 8
post-infectious blood meal can inhibit sporozoite invasion
of salivary glands [30]. It was hypothesized that anti-CS
antibody induced by RTS,S/AS01 could affect oocyst
formation and/or sporogony in the mosquito host.
Under the conditions of this study, however, serum IgGs
from RTS,S vaccinated children did not show significant
inhibition in oocyst intensity, oocyst prevalence or
sporozoite intensity. Similar experiments with two anti-
CS human monoclonal antibodies used at over 30-fold
higher levels of anti-CS specific antibodies also showed
no significant reduction in oocyst intensity or preva-
lence, and the reduction in sporozoite intensity seen in
isolated experiments was not consistent.
It is likely that for an effect of anti-CS antibodies
against sporogony to occur in mosquitoes, the antibodies
should be present in the right anatomical compartment
at sufficient concentration. That was likely the case in
past studies that demonstrated the role of CS in the
physiology of sporogony [13,29]. This study suggests
that the concentration of anti-CS antibodies reaching
the relevant mosquito anatomic compartment following
feeding on a RTS,S-vaccinated individual is too low to
produce an inhibition in sporogony. Similar negative re-
sults were obtained when evaluating the effect of human
anti-sporozoite antibodies induced either by natural in-
fection [16,18] or inoculation of irradiated sporozoites
[15] on the sporozoite numbers in mosquitoes. Hypo-
thetical vaccine strategies inducing higher anti-CS anti-
body titres may show some inhibition, but it is unlikely
considering the results of this study where anti-CS
monoclonal antibodies used at high concentration failed
to show any consistent inhibitory effect. Besides the anti-
body titre, the fine specificity could affect the results.
The C-terminus and N-terminus portions of CS protein
have different functions [10]. Since the RTS,S vaccine
Table 5 Transmission-blocking activities of human mAb fed three days post-infected blood meala
Sample Mean oocb PIm[o]c p-valued Mosquitoe PIp[o]f p-valueg Mean Spzh PIm[s]i
MAL1C 15.1 2 0.97 1/20 -27 0.08 9.0 53
(0, 36) (-185, 65) (-80, 3)
MAL2A 11.6 24 0.64 1/20 -27 0.08 19.8 -4
(0, 30) (-119, 74) (-80, 3)
Contl 15.3 N/A N/A 5/20 N/A N/A 19.0 N/A
(0, 44)
aAll mAb were tested at 0.231 mg/ml and fed three days post-infected blood meal.
bArithmetic mean (range) of oocysts per mosquito midgut.
cPer cent inhibition of mean oocyst intensity (PIm[o]) and the 95% confidence interval (95% CI).
dTwo-sided p-values for testing whether PIm[o] is significantly different from 0.
eNumber of mosquitoes without any oocysts/number of mosquitoes examined.
fPer cent inhibition of prevalence of mosquitoes with oocysts (PIp[o]) and the 95% CI.
gp-values of PIp[o].
hNumber of sporozoites (×103) per mosquito calculated from a pool of salivary glands of 12 mosquitoes.
iPer cent inhibition of mean sporozoite intensity (PIm[s]).
Table 6 Transmission-blocking activities of human mAb fed six days post-infected blood meala
Sample Mean oocb PIm[o]c p-valued Mosquitoe PIp[o]f p-valueg Mean Spzh PIm[s]i
MAL1C 48.5 -49 0.44 2/20 10 0.15 50.3 -129
(0, 88) (-331, 49) (-8, 30)
MAL2A 42.1 -29 0.61 0/20 0 1.00 23.3 -6
(20, 82) (-287, 54) (-19, 16)
Contl 32.6 N/A N/A 0/20 N/A N/A 22.0 N/A
(11, 64)
aAll mAb were tested at 0.231 mg/ml and fed six days post-infected blood meal.
bArithmetic mean (range) of oocysts per mosquito midgut.
cPer cent inhibition of mean oocyst intensity (PIm[o]) and the 95% confidence interval (95% CI).
dTwo-sided p-values for testing whether PIm[o] is significantly different from 0.
eNumber of mosquitoes without any oocysts/number of mosquitoes examined.
fPer cent inhibition of prevalence of mosquitoes with oocysts (PIp[o]) and the 95% CI.
gp-values of PIp[o].
hNumber of sporozoites (×103) per mosquito calculated from a pool of salivary glands of 12 mosquitoes.
i Per cent inhibition of mean sporozoite intensity (PIm[s]).
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antigen does not include the N-terminal portion of CS,
it was not possible to evaluate the effect of antibodies
targeting the N-terminus of the protein in this study.
An alternative explanation of the negative results in this
study might be linked to inherent variability in the labour-
intensive biological assay, with highly variable numbers of
oocysts and sporozoites within the same COM in the
same feeding experiment (see [21] for discussion of this
variability with respect to the oocyst counts). Indeed, the
estimates of PIm[o] and PIm[s] had large 95% CIs. Other
studies were also affected by this variability; 75% inhibition
in PIm[s] did not reach significance (p = 0.06) in one study
[31], and 90% inhibition in PIm[s] barely attained signifi-
cance (p = 0.04) in another study [14]. While it would have
been ideal to perform the study with more samples (e.g.,
test individual serum samples, instead of 6 pools) and re-
peat the assays many times to overcome the variability,
the volumes of test materials which were available for
this study were limited. In order to reduce the impact of
the high variability in oocyte and sporozoite numbers,
the anti-CS IgGs and control IgGs were also compared
as groups. This analysis also failed to show any inhib-
ition of sporogony.
A possible experimental limitation relates to the fact
that the numbers of oocysts and sporozoites per mos-
quito are considerably higher in the SMFA than seen in
natural infections in field-caught mosquitoes. Experi-
ments with lower infection levels are complicated by the
increased likelihood of mosquitoes in the control groups
having no oocysts/sporozoites. Although unlikely in view
of the results of this study, an effect under conditions of
lower infectivity cannot be ruled out.
Another possible factor determining the inhibitory effect
of ingested antibodies on sporogony is the timing of inges-
tion relative to the stage of the parasite life cycle. In past
studies, researchers used different days, ranging from five
to eleven days after the initial feed, to evaluate the effect
[12,14-18,31]. In this study, the mosquitoes were chal-
lenged with the test antibodies three or six days after the
initial gametocyte feed in the serial-feed experiments. Fur-
ther investigations would be required to evaluate the effect
of delaying a second feed. Relevance to mosquito behav-
iour in nature would need to be considered,
Conclusions
Previous studies have clearly shown that CS protein has a
significant role in sporozoite development in mosquitoes.
Keeping in mind the limitations of the experimental ap-
proach (oocyst and sporozoite count variability, limited
sample volume available for testing, high infectivity com-
pared to nature, serial feeding to day 6 only), this study
does not support the concept that antibodies induced by
the RTS,S/AS01 vaccine in human noticeably reduce mal-
aria transmission by blocking sporozoite development or
salivary gland invasion in mosquitoes when taken up dur-
ing feeding. Whether RTS,S/AS01 vaccine may reduce
transmission in a population through the ability of pre-
erythrocytic immunity to prevent new infections remains
to be evaluated.
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